GNFT Stock Analysis: Genfit S.A. | PA
Biotechnology | PA, France | Market Cap: 521m EUR | 12M Return: 187.3% | FR0004163111 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.89M
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Genfit S.A. is a France-headquartered biopharmaceutical company that focuses on the research and development of therapeutics and non-invasive diagnostics, primarily for liver-related diseases. The company operates a dual business model spanning drug development and molecular diagnostics, which is relatively uncommon among small-cap clinical-stage biotechs and helps diversify revenue potential beyond a single therapeutic candidate.
Its lead asset, elafibranor, is being commercialized through a strategic partnership with Ipsen and is indicated for primary biliary cholangitis (PBC), with additional Phase 3 development in primary sclerosing cholangitis. Other clinical-stage programs include GNS561 (Phase 1b) for cholangiocarcinoma and G1090N/NTZ (Phase 1) for acute-on-chronic liver failure, alongside a preclinical pipeline targeting conditions such as hepatic encephalopathy and urea cycle disorders.
On the diagnostics side, Genfit has partnered with Labcorp to commercialize NASHnext, a blood-based molecular test for metabolic dysfunction-associated steatohepatitis (MASH), as well as TS-01, a diagnostic tool for measuring blood ammonia levels. The company was incorporated in 1999 and is listed on the Euronext Paris exchange under the ticker GNFT, with a small-cap market capitalization of approximately $530 million USD.
- Elafibranor PBC launch drives milestone revenue from Ipsen partnership
- GNS561 cholangiocarcinoma Phase 1b data readout ahead
- NASHnext diagnostic sales scale with Labcorp commercialization
| Net Income: -102.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 6.95 > 1.0 |
| NWC/Revenue: 98.39% < 20% (prev 252.3%; Δ -153.9% < -1%) |
| CFO/TA 0.05 > 3% & CFO 8.37m > Net Income -102.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.2m) vs 12m ago -16.79% < -2% |
| Gross Margin: 1.91% > 18% (prev 99.12%; Δ -97.21% > 0.5%) |
| Asset Turnover: 28.64% > 50% (prev 20.83%; Δ 7.81% > 0%) |
| Interest Coverage Ratio: -3.61 > 6 (EBIT TTM -69.1m / Interest Expense TTM 19.2m) |
| A: 0.34 (Total Current Assets 141.4m - Total Current Liabilities 89.3m) / Total Assets 153.6m |
| B: -3.27 (Retained Earnings -502.0m / Total Assets 153.6m) |
| C: -0.37 (EBIT TTM -69.1m / Avg Total Assets 185.1m) |
| D: -0.24 (Book Value of Equity -49.5m / Total Liabilities 202.1m) |
| Altman-Z'' = -11.20 = D |
| DSRI: 0.57 (Receivables 24.8m/36.9m, Revenue 53.0m/45.1m) |
| GMI: 51.98 (GM 99.12% / 1.91%) |
| AQI: 0.14 (AQ_t 0.04 / AQ_t-1 0.25) |
| SGI: 1.17 (Revenue 53.0m / 45.1m) |
| TATA: -0.72 (NI -102.1m - CFO 8.37m) / TA 153.6m) |
| Beneish M = 42.35 (Cap -4..+1) = D |
As of November 14, 2026, the stock is trading at EUR 10.70 with a total of 161,215 shares traded. Over the past week, the price has changed by +0.94%, over one month by +35.61%, over three months by -19.91% and over the past year by +187.33%.
Current recommended Stop Loss: 8.80 (which is 17.8% or 2.6 ATR below the current price).
Genfit S.A. has no consensus analysts rating.
P/E Forward = 7.5472
P/S = 8.797
P/B = 3.3353
Revenue TTM = 53.0m EUR
EBIT TTM = -69.1m EUR
EBITDA TTM = -18.3m EUR
Long Term Debt = 109.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 68.0m EUR (from shortTermDebt, last quarter)
Debt = 182.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.33m
Net Debt = 68.8m EUR (calculated: Debt 182.6m - CCE 113.8m)
Enterprise Value = 590.1m EUR (521.3m + Debt 182.6m - CCE 113.8m)
Interest Coverage Ratio = -3.61 (Ebit TTM -69.1m / Interest Expense TTM 19.2m)
EV/FCF = 78.72x (Enterprise Value 590.1m / FCF TTM 7.50m)
FCF Yield = 1.27% (FCF TTM 7.50m / Enterprise Value 590.1m)
FCF Margin = 14.14% (FCF TTM 7.50m / Revenue TTM 53.0m)
Net Margin = -192.6% (Net Income TTM -102.1m / Revenue TTM 53.0m)
Gross Margin = 1.91% ((Revenue TTM 53.0m - Cost of Revenue TTM 52.0m) / Revenue TTM)
Gross Margin QoQ = 90.09% (prev -56.26%)
Tobins Q-Ratio = 3.84 (Enterprise Value 590.1m / Total Assets 153.6m)
Interest Expense / Debt = 10.50% (Interest Expense 19.2m / Debt 182.6m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -51.8m (EBIT -69.1m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.58 (Total Current Assets 141.4m / Total Current Liabilities 89.3m)
Debt / Equity = -3.69 (negative equity) (Debt 182.6m / totalStockholderEquity, last quarter -49.5m)
Debt / EBITDA = -3.77 (negative EBITDA) (Net Debt 68.8m / EBITDA -18.3m)
Debt / FCF = 9.18 (Net Debt 68.8m / FCF TTM 7.50m)
Total Stockholder Equity = 12.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.17% (Net Income -102.1m / Total Assets 153.6m)
RoE = -841.6% (Net Income TTM -102.1m / Total Stockholder Equity 12.1m)
RoCE = -57.03% (EBIT -69.1m / Capital Employed (Equity 12.1m + L.T.Debt 109.1m))
RoIC = -39.98% (negative operating profit) (NOPAT -51.8m / Invested Capital 129.7m)
WACC = 7.23% (E(521.3m)/V(703.9m) * Re(7.01%) + D(182.6m)/V(703.9m) * Rd(10.50%) * (1-Tc(0.25)))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 9.47 | Cagr: 0.50%
[DCF] Terminal Value 75.44% ; FCFF base≈7.50m ; Y1≈7.53m ; Y5≈7.97m
[DCF] Fair Price = 1.10 (EV 124.0m - Net Debt 68.8m = Equity 55.2m / Shares 50.0m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 46.95 | Revenue CAGR: 32.18% | SUE: N/A | # QB: 0
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=-0.12 | Chg30d=+33.92% | Revisions=-25% | GrowthEPS=+74.6% | GrowthRev=+13.2%
EPS next Year (2027-12-31): EPS=0.18 | Chg30d=+92.51% | Revisions=-25% | GrowthEPS=+250.0% | GrowthRev=+59.4%